共 94 条
- [1] Bozkurt B(2021)Universal definition and classification of heart failure J Cardiac Fail 27 P387-413
- [2] Borlaug BA(2011)Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment Eur Heart J 32 670-679
- [3] Zile MR(2001)Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation 104 779-782
- [4] Shah S(2020)Research priorities for heart failure with preserved ejection fraction. National Heart, lung and blood institute working group summary Circulation 141 1001-1026
- [5] Solomon SD(2019)Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction N Engl J Med 381 1609-1620
- [6] Pitt B(2014)TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction N Engl J Med 370 1383-1392
- [7] Flather MD(2005)Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure-SENIORS Eur Heart J 26 215-25
- [8] Anker SD(2021)Empagliflozin in heart failure with a preserved ejection fraction; the EMPEROR-Preserved trial N Engl J Med 385 1451-1461
- [9] McMurray JJV(2020)Effects of sacubitril-valsartan versus valsartan in women compared to men with heart failure and preserved ejection fraction Circulation 141 338-351
- [10] Solomon SD(2016)Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction Eur Heart J 37 455-462